TxCell re-acquires full rights to its lead product Ovasave
French biotech firm TxCell (Euronext Paris: TXCL), which is developing innovative, personalized cell immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, has agreed with Trizell Holding, an affiliate of the Dr Frederik Paulsen Foundation, to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave.
The agreement granted Trizell an exclusive option to in-license development and commercialization rights to Ovasave, an antigen-specific Treg cell-based immunotherapy, in inflammatory bowel disease, including Crohn’s disease. The collaboration on Ovasave that TxCell previously had with privately-held Switzerland-headquartered Ferring International was assigned to Trizell early this year (The Pharma Letter January 4). TxCell has now regained full rights to Ovasave.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze